



Docket No.: 244295US0CONT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RE: Application Serial No.: 10/691,654
Applicants: Tomoko MAEDA, et al.
Filing Date: October 24, 2003
For: METHODS FOR ISOLATION OF OSTEOCLAST
PRECURSOR CELLS AND INDUCING THEIR
DIFFERENTIATION INTO OSTEOCLASTS
Group Art Unit: 1651
Examiner: Vera Afremova

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon


Daniel J. Pereira, Ph.D.

Registration No. 45,518

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)



DOCKET NO: 244296US0CONT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
TOMOKO MAEDA, ET AL. : EXAMINER: VERA AFREMOVA
SERIAL NO: 10/691,654 :
FILED: OCTOBER 24, 2003 : GROUP ART UNIT: 1651
FOR: METHODS FOR ISOLATION OF :
OSTEOCLAST PRECURSOR
CELLS AND INDUCING THEIR
DIFFERENTIATION INTO
OSTEOCLASTS

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Restriction Requirement mailed May 03, 2005, Applicants elect, with traverse, Group I: Claims 21-25, drawn to a method for producing an osteoclast precursor cell, for further prosecution.

REMARKS

The Examiner is requiring restriction of the above-identified application as follows:

Group I: Claims 21-25, drawn to a method for producing an osteoclast precursor cell;
Group II: Claim 26, drawn to an osteoclast precursor cell;
Group III: Claims 27-36, drawn to a method for producing an osteoclast;
Group IV: Claim 37, drawn to an osteoclast;
Group V: Claims 38 and 39, drawn to a method for screening an agent for treating metabolic bone disease by using an osteoclast precursor cell;